Giant Biogene Holding Co., Ltd. (HKG:2367)
Hong Kong · Delayed Price · Currency is HKD 30.96
+0.64 (2.11%)
May 12, 2026, 4:08 PM HKT
Giant Biogene Holding Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 1,915 | 2,062 | 1,452 | 1,002 | 828.13 |
Depreciation & Amortization | 81.92 | 48.98 | 33.69 | 27.24 | 23.94 |
Other Amortization | 0.38 | -0.34 | 0.48 | 0.39 | 0.27 |
Loss (Gain) From Sale of Assets | -1.17 | -0.56 | 2.88 | 2.91 | 0.18 |
Loss (Gain) From Sale of Investments | -49.93 | -43.27 | -29.33 | 8.28 | -14.47 |
Loss (Gain) on Equity Investments | -9.5 | 3.6 | - | - | - |
Stock-Based Compensation | 45.24 | 89.72 | 20.52 | 17.66 | 16.49 |
Provision & Write-off of Bad Debts | -0.64 | 0.94 | -0.03 | -0.15 | 0.05 |
Other Operating Activities | -162.3 | -93.98 | 39.65 | 4.94 | -104.34 |
Change in Accounts Receivable | -59.94 | -40.2 | -32.58 | -3.64 | -11.16 |
Change in Inventory | -82.48 | -113.51 | -17.77 | -94.36 | -24.61 |
Change in Accounts Payable | -88.14 | 153.6 | 78.46 | 31.04 | -8.33 |
Change in Unearned Revenue | -1.91 | -19.22 | 24.7 | -3.23 | 13.54 |
Change in Other Net Operating Assets | 194.25 | -6.92 | 75.01 | -61.49 | -27.28 |
Operating Cash Flow | 1,781 | 2,041 | 1,647 | 931.64 | 692.4 |
Operating Cash Flow Growth | -12.77% | 23.90% | 76.83% | 34.55% | -16.99% |
Capital Expenditures | -428.1 | -246.77 | -226.3 | -152.66 | -75 |
Sale of Property, Plant & Equipment | 7.2 | - | - | - | - |
Cash Acquisitions | -2.16 | - | - | - | - |
Divestitures | - | -3.69 | 33.13 | - | - |
Sale (Purchase) of Intangibles | -0.72 | -0.01 | -2.13 | -0.59 | -0.13 |
Sale (Purchase) of Real Estate | - | - | - | - | -19.53 |
Investment in Securities | -62.63 | -967 | -379.47 | -718.65 | 1,447 |
Other Investing Activities | 167.68 | 111.35 | 47.49 | 13.16 | 210.72 |
Investing Cash Flow | -318.74 | -1,106 | -527.28 | -858.74 | 1,563 |
Long-Term Debt Repaid | -7.25 | -4.18 | -1.05 | -0.19 | - |
Net Debt Issued (Repaid) | -7.25 | -4.18 | -1.05 | -0.19 | - |
Issuance of Common Stock | 2,382 | 1,504 | 56.4 | 583.51 | 0.06 |
Repurchase of Common Stock | -166.15 | - | - | -6,236 | - |
Common Dividends Paid | -644.79 | -908.44 | - | - | - |
Dividends Paid | -644.79 | -908.44 | - | -367.46 | -2,550 |
Other Financing Activities | -11.29 | -7.97 | -3.54 | -11.67 | -68.62 |
Financing Cash Flow | 917.99 | 582.95 | 51.81 | -5,790 | 4,476 |
Foreign Exchange Rate Adjustments | -103.93 | 8.18 | 1.09 | -55.18 | 3.98 |
Net Cash Flow | 2,276 | 1,526 | 1,173 | -5,772 | 6,735 |
Free Cash Flow | 1,353 | 1,794 | 1,421 | 778.97 | 617.4 |
Free Cash Flow Growth | -24.63% | 26.27% | 82.44% | 26.17% | -18.62% |
Free Cash Flow Margin | 24.51% | 32.40% | 40.33% | 32.95% | 39.77% |
Free Cash Flow Per Share | 1.28 | 1.79 | 1.45 | 0.76 | 0.62 |
Cash Income Tax Paid | 447.58 | 385 | 205.76 | 172.7 | 218.26 |
Levered Free Cash Flow | 819.89 | 1,441 | 1,057 | -6,104 | 5,352 |
Unlevered Free Cash Flow | 820.08 | 1,441 | 1,057 | -6,104 | 5,352 |
Change in Working Capital | -38.22 | -26.24 | 127.81 | -131.67 | -57.85 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.